Online inquiry

IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ7173MR)

This product GTTS-WQ7173MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL), Follicular lymphoma research.

Specifications
Product type	mRNA
Modified bases	5-Methoxy-UTP
5' Cap	Cap 0
Species	Chimeric
RefSeq	NM_001178098.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	930
UniProt ID	P15391

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ7173MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ824MR	IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	ABBV-085
GTTS-WQ5487MR	IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, Pseudo-UTP, 120 nt-poly(A))	mRNA	CDP 6038
GTTS-WQ14999MR	IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, Pseudo-UTP, 120 nt-poly(A))	mRNA	SJ25C1 scFv-28Z CAR
GTTS-WQ9124MR	IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	IMGN242
GTTS-WQ6574MR	IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	DC-1630423
GTTS-WQ15622MR	IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	VAY-736
GTTS-WQ3738MR	IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	BAY-1093884
GTTS-WQ197MR	IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, 2-Thio-UTP, 30 nt-poly(A))	mRNA	12-IgG1

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST